Schaffrath Judith, Schmoll Hans-Joachim, Voigt Wieland, Müller Lutz P, Müller-Tidow Carsten, Mueller Thomas
Department of Internal Medicine IV, Oncology/Hematology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Workgroup Clinical Studies in Oncology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
PLoS One. 2017 Jun 7;12(6):e0178930. doi: 10.1371/journal.pone.0178930. eCollection 2017.
The in vitro activity of kinase inhibitors targeting mTOR (RAD001), EGFR, HER2/neu, VEGFR (AEE788) and IGF-1R (AEW541) alone or in combination with cisplatin was tested in the cisplatin sensitive TGCT cell lines H12.1 and GCT72 as well as in the resistant cell lines H12.1RA, H12.1D, 1411HP and 1777NRpmet using the sulforhodamin-B-(SRB)-cytotoxicity-assay. To evaluate the activity of the kinase inhibitors, western blot analysis of the targeted receptors and their phosphorylated state was performed before and after exposure to each substance.
The different kinase inhibitors demonstrated significant cell growth inhibition in both cisplatin sensitive and resistant cell lines. The examined cell lines showed different protein expression levels of the targeted receptors. However there was no correlation between the targeted receptor expression and phosphorylation level and the antiproliferative effect of the respective agent. Furthermore, the combination of cisplatin and the kinase inhibitors exerted both additive and antagonistic effects in the studied cell lines.
Our data suggest potential activity of the investigated kinase inhibitors in both cisplatin sensitive and resistant TGCT cell lines as a single agent. However, when combined with cisplatin they did not demonstrate any promising ability to overcome cisplatin resistance in TGCTs.
使用磺酰罗丹明 B(SRB)细胞毒性测定法,在顺铂敏感的睾丸生殖细胞瘤(TGCT)细胞系 H12.1 和 GCT72 以及耐药细胞系 H12.1RA、H12.1D、1411HP 和 1777NRpmet 中,测试了靶向 mTOR(RAD001)、表皮生长因子受体(EGFR)、人表皮生长因子受体 2/神经(HER2/neu)、血管内皮生长因子受体(VEGFR,AEE788)和胰岛素样生长因子 1 受体(IGF-1R,AEW541)的激酶抑制剂单独或与顺铂联合使用时的体外活性。为了评估激酶抑制剂的活性,在暴露于每种物质之前和之后,对靶向受体及其磷酸化状态进行了蛋白质印迹分析。
不同的激酶抑制剂在顺铂敏感和耐药细胞系中均显示出显著的细胞生长抑制作用。所检测的细胞系显示出靶向受体的不同蛋白质表达水平。然而,靶向受体的表达和磷酸化水平与相应药物的抗增殖作用之间没有相关性。此外,顺铂与激酶抑制剂的联合在研究的细胞系中产生了相加和拮抗作用。
我们的数据表明,所研究的激酶抑制剂作为单一药物在顺铂敏感和耐药的 TGCT 细胞系中均具有潜在活性。然而,当与顺铂联合使用时,它们并未显示出任何克服 TGCT 中顺铂耐药性的有前景的能力。